Our findings show that the USP14 inhibitor IU1 significantly increases the sensitivity of GSC-derived brain tumor xenografts to IR therapy, supporting the idea of targeting USP14 to enhance standard GBM treatment strategies. Here, USP14 is linked to glioblastoma.